European consensus on grading bone marrow fibrosis and assessment of cellularity

Haematologica

Volumn 90, Issue 8, 2005, Pages 1128-1132

  Thiele, Jürgen ^a   Kvasnicka, Hans Michael ^a   Facchetti, Fabio ^b   Franco, Vito ^c   Van Der Walt, Jon ^d   Orazi, Attilio ^e  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Spedali Civili ^*  (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e INDIANA UNIVERSITY   (United States)

Author keywords

Bone marrow; Cellularity; Grading of myelofibrosis; Standardization; Trephine biopsies

Indexed keywords

ARTICLE; BONE MARROW BIOPSY; BONE MARROW CELL; CELL DIFFERENTIATION; CONSENSUS DEVELOPMENT; EUROPE; HEMATOPOIETIC CELL; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MYELOFIBROSIS; PRACTICE GUIDELINE; REPRODUCIBILITY; RISK ASSESSMENT; SCORING SYSTEM; STANDARDIZATION;

BONE MARROW; EUROPE; HUMANS; MYELOFIBROSIS; REPRODUCIBILITY OF RESULTS;

EID: 24944524079     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Rosenthal NS, Farhi DC, Fox RM, Lazarus HM. Marrow cellularity as a predictor of adequate cell yield for transplantation. Am J Clin Pathol 1994;101:81-4.
2. Le Bousse-Kerdiles MC, Martyre MC. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. Ann Hematol 1999;78:437-44.
3. Frisch B, Bard R, Burkhardt R. Bone marrow biopsy in clinical medicine: an overview. Haematologia (Budap) 1982;15:245-85.
4. Aharon A, Levy Y, Bar-Dayan Y, Afek A, Zandman-Goddard G, Skurnik Y, et al. Successful treatment of early secondary myelofibrosis in SLE with IVIG. Lupus 1997;6:408-11.
5. Thiele J, Langohr J, Skorupka M, Fischer R. Reticulin fibre content of bone marrow infiltrates of malignant non-Hodgkin's lymphomas (B-cell type, low malignancy)-a morphometric evaluation before and after therapy. Virchows Arch A Pathol Anat Histopathol 1990;417:485-92.
6. Schmidt U, Ruwe M, Leder LD. Multiple myeloma with bone marrow biopsy features simulating concomitant chronic idiopathic myelofibrosis. Nouv Rev Fr Hematol 1995;37:159-63.
7. Lambertenghi-Deliliers G, Orazi A, Luksch R, Annaloro C, Soligo D. Myelodysplastic syndrome with, increased marrow fibrosis: a distinct clinicopathological entity. Br J Haematol 1991;78:161-6.
8. Maschek H, Georgii A, Kaloutsi V, Werner M, Bandecar K, Kressel MG, et al. Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients. Eur J Haematol 1992;48:208-14.
9. Thiele J, Grashof K, Fisher R. Follow-up study on bone marrow reticulin fibrosis in AML. Anal Cell Pathol 1991;3:225-31.
10. Orazi A, O'Malley DP, Jiang J, Vance GH, Thomas J, Czader M, et al. Acute panmyelosis with myelofibrosis: an entity distinct from acute megakaryoblastic leukemia. Mod Pathol 2004:1-12.
11. Buhr T, Georgii A, Choritz H. Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification. Pathol Res Pract 1993;189:121-32.
12. Georgii A, Buhr T, Buesche G, Kreft A, Choritz H. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leuk Lymphoma 1996;22 Suppl 1:15-29.
13. Georgii A, Buesche G, Kreft A. The histopathology of chronic myeloproliferative diseases. Baillieres Clin Haematol 1998;11:721-49.
14. Buhr T, Busche G, Choritz H, Langer F, Kreipe H. Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens. Am J Clin Pathol 2003;119:152-8.
15. Thiele J, Kvasnicka HM, Schmitt-Graeff A, Diehl V. Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients. Leuk Lymphoma 2003;44:949-53.
16. Lazzarino M, Morra E, Castello A, Inverardi D, Coci A, Pagnucco G, et al. Myelofibrosis in chronic granulocytic leukaemia: clinicopathologic correlations and prognostic significance. Br J Haematol 1986;64:227-40.
17. Dekmezian R, Kantarjian HM, Keating MJ, Talpaz M, McCredie KB, Freireich EJ. The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer 1987;59:1739-43.
18. Thiele J, Kvasnicka HM, Titius BR, Parpert U, Nebel R, Zankovich R, et al. Histological features of prognostic significance in CML-an immunohistochemical and morphometric study (multivariate regression analysis) on trephine biopsies of the bone marrow. Ann Hematol 1993;66:291-302.
19. Kvasnicka HM, Thiele J, Schmitt-Graeff A, Diehl V, Zankovich R, Niederle N, et al. Prognostic impact of bone marrow erythropoietic precursor cells and myelofibrosis at diagnosis of Ph1+ chronic myelogenous leukaemia-a multicentre study on 495 patients. Br J Haematol 2001;112:727-39.
20. Buesche G, Hehlmann R, Hecker H, Heimpel H, Heinze B, Schmeil A, et al. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial. Leukemia 2003;17:2444-53.
21. Rajantie J, Sale GE, Deeg HJ, Amos D, Appelbaum F, Storb R, et al. Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradiotherapy and allogeneic bone marrow transplantation. Blood 1986;67:1693-7.
22. Thiele J, Kvasnicka HM, Beelen DW, Zirbes TK, Jung F, Reske D, et al. Relevance and dynamics of myelofibrosis regarding hematopoietic reconstitution after allogeneic bone marrow transplantation in chronic myelogenous leukemia-a single center experience on 160 patients. Bone Marrow Transplant 2000;26:275-81.
23. Barosi G, Elliott MA, Canepa L, Ballerini F, Piccaluga PP, Visani G, et al. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. Leuk Lymphoma 2002;43:2301-7.
24. Tefferi A. Treatment approaches in myelofibrosis with myeloid metaplasia: the old and the new. Semin Hematol 2003;40:18-21.
25. Dingli D, Mesa RA, Tefferi A. Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment. Intern Med 2004;43:540-7.
26. Mesa RA, Elliott MA, Schroeder G, Tefferi A. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc 2004;79:883-9.
27. Hartsock RJ, Smith EB, Petty CS. Normal variations with aging of the amount of hematopoietic tissue in bone marrow from the anterior iliac crest. A study made from 177 cases of sudden death examined by necropsy. Am J Clin Pathol 1965;43:326-31.
28. Gruppo RA, Lampkin BC, Granger S. Bone marrow cellularity determination: comparison of the biopsy, aspirate, and buffy coat. Blood 1977;49:29-31.
29. Fong TP, Okafor LA, Schmitz TH, Thomas W, Westerman MP. An evaluation of cellularity in various types of bone marrow specimens. Am J Clin Pathol 1979;72:812-6.
30. Paul M, Chandy M, Pulimood R, Krishnaswami H. Cellularity of bone marrow: a comparison of trephine biopsies and aspirate smears. Indian J Pathol Microbiol 1989;32:186-9.
31. Frisch B, Bartl R. Atlas of bone marrow pathology. London: Kluwer. 1990:10-1.
32. Bauermeister DE. Quantitation of bone marrow reticulin - a normal range. Am J Clin Pathol 1971;56:24-31.
33. Manoharan A, Horsley R, Pitney WR. The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol 1979;43:185-90.
34. Pasquale D, Chikkappa G. Comparative evaluation of bone marrow aspirate particle smears, biopsy imprints, and biopsy sections. Am J Hematol 1986;22:381-9.
35. Beckman EN, Brown AW, Jr. Normal reticulin level in iliac bone marrow. Arch Pathol Lab Med 1990;114:1241-3.
36. Thiele J, Kvasnicka HM, Werden C, Zankovich R, Diehl V, Fischer R. Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. Leuk Lymphoma 1996;22:303-17.
37. Kvasnicka HM, Thiele J, Werden C, Zankovich R, Diehl V, Fischer R. Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer 1997;80:708-19.
38. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 1999;17:2954-70.
39. Thiele J, Kvasnicka HM, Schmitt-Graeff A, Bundschuh S, Biermann T, Roessler G, et al. Effects of chemotherapy (busulfan-hydroxyurea) and interferon-α on bone marrow morphologic features in chronic myelogenous leukemia. Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features. Am J Clin Pathol 2000;114:57-65.
40. Thiele J, Kvasnicka HM, Schmitt-Graeff A, Diehl V. Bone marrow histopathology following cytoreductive therapy in chronic idiopathic myelofibrosis. Histopathology 2003;43:470-9.